The US Food and Drug Administration (USFDA) has flagged manufacturing lapses at Natco Pharma’s Telangana plant. The regulatory scrutiny follows an inspection revealing deficiencies in manufacturing practices. Natco Pharma, a prominent player in the pharmaceutical industry, faces regulatory action as a result of these identified lapses.